Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

INFECTED CELLS ARE CLONOTYPICALLY DIVERSE IN BLOOD & LYMPH NODES SINCE FIEBIG STAGE I

By Jimmy He PharmD, DScApril 22, 2021

…and lymph nodes since the earliest stage of acute infection (Fiebig I) and their frequency increased with time. Phenotypic analysis of 12,067 p24+ cells from blood and lymph nodes showed…

PROPORTION OF INDUCIBLE AND INTACT HIV-1 IN BLOOD IS REFLECTIVE OF LYMPH NODES

By Enthusiast Inc MDMarch 5, 2019

…virus was median=9.9%. Only a small proportion of the intact provirus population was inducible (median=5.7%, IQR=3.3-10.8%) with an even smaller subset of inducible defective provirus (median=1.3%, IQR=0.9-2.3%). Intact and inducible…

EFFECT OF SEX, SHIV, AND DRUG TRANSPORTERS ON LYMPH NODE ANTIRETROVIRAL PENETRATION

By Enthusiast Inc MDMarch 5, 2018

…presented as geometric mean (median range) and geometric mean ratio (GMR). Analyses were performed using Pearson Correlation, Kruskall-Wallis, and Mann-Whitney Rank Sum tests (p<0.05). ARV concentrations are summarized in the…

1293 – Dynamic Choice HIV Prevention With Cabotegravir (CAB-LA): A Model-Based Cost-Effectiveness Analysis

By Jimmy He PharmD, DScMarch 20, 2025

…proportion of people with a current PrEP/PEP indication who take PrEP/PEP and hence reduce HIV incidence relative to status quo over 10 years; median (90% range) across setting-scenarios HIV incidence…

DETECTION OF ANTI-ASP ANTIBODIES IN SERA OF HIV+ INDIVIDUALS

By Enthusiast Inc MDMarch 5, 2018

…by ELISA using 7 overlapping peptides spanning the whole ASP. 96-well flat-bottom plates were coated overnight with the synthetic peptides (1 peptide/well). Sera were diluted 1:200 prior to screening. Goat…

HIV Inhibition and Variation in Anti-Microbial Peptides Associated With Intercourse

By Enthusiast Inc MDSeptember 29, 2014

…protease inhibitor (SLPI), and lysozyme – at the time of PVI (compared to a neutral control for time levels) and assesses effects on in-vitro HIV inhibition. Methodology: 40 healthy women…

PEPFAR DREAMS INTERVENTION AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN RAKAI, UGANDA

By Jimmy He PharmD, DScApril 28, 2020

In 2016, the Presidents Emergency Plan for AIDS Relief (PEPFAR) initiated the DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women) programs in10 sub-Saharan Africa countries including Uganda to reduce risk of HIV and domestic…

470 – Panviral Antibody Reactome Profiles Associate With Cognition in People With HIV

By Jimmy He PharmD, DScMarch 31, 2026

…Self-Assembly platform measuring IgG binding to 286,793 peptides from >500 viruses. Analyses included antibodies reactive in ≥10% of cohort. Associations with CI (global and seven cognitive domains) were evaluated using…

Cross-Clade Inhibition of HIV on Primary Cells by CXCR4 or CCR5 Fused to the C34 Peptide from gp41 HR2

By Enthusiast Inc MDSeptember 29, 2014

…from HIV infection. Previously we described a 34 amino acid peptide from the C-terminal heptad repeat-2 domain of gp41 (C34) which, when fused to the amino terminus (NT) of either…

Objective Assessment of Doxycycline PEP Use Among Cisgender Women in Kenya

By Jimmy He PharmD, DScMarch 6, 2024

Background: Doxycycline postexposure prophylaxis taken following a condomless sexual exposure reduces incident bacterial STIs among men who have sex with men but not among cisgender women in initial trials. Adherence…

←1
2345678910111213
…1415161718…
19202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top